EHA 2023 | REVEAL study: long-term analysis of ruxolitinib in patients with polycythemia vera after hydroxyurea
Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, shares the results of a longitudinal analysis from the REVEAL study (NCT02252159) examining the characteristics and clinical outcomes of patients with polycythemia vera (PV) who switched from hydroxyurea to ruxolitinib. The study showed that ruxolitinib led to significant improvements in PV-related symptoms and the need for phlebotomy. These findings underscore the effectiveness of ruxolitinib as a second-line treatment option for patients with PV. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting or Advisory Role – Constellation Pharmaceuticals; La Jolla Pharma; Novartis; Sierra Oncology
Research Funding – Abbvie (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); CTI (Inst); Genentech (Inst); Incyte (Inst); Mays Cancer Center (Inst); NCI (Inst); Promedior (Inst); Samus (Inst)
